Argos Therapeutics advised to halt study

An independent data monitoring committee recommended that Argos Therapeutics Inc. (Nasdaq: ARGS) discontinue its Phase 3 ADAPT clinical trial of rocapuldencel-T for futility. The stock price plummeted $2.92 to close at $1.47.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.